Cantor Fitzgerald analyst Josh Schimmer downgraded 4D Molecular to Neutral from Overweight.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FDMT:
- RBC says 4D Molecular ‘oversold’ after ‘right decision’ about Phase 3 pivot
- 4D Molecular falls after wet AMD data is viewed as mixed
- 4D Molecular price target raised to $39 from $38 at Chardan
- 4D Molecular announces data from PRISM, 4FRONT trials
- 4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day